STOCK TITAN
  1. Home
  2. News
  3. MEDIF

MEDIPHARM LABS CORP - MEDIF STOCK NEWS

Welcome to our dedicated page for MEDIPHARM LABS news (Ticker: MEDIF), a resource for investors and traders seeking the latest updates and insights on MEDIPHARM LABS stock.

MediPharm Labs Corp (MEDIF) is a pharmaceutical company specializing in precision-based cannabinoids. With GMP certification from ANVISA, FDA, EU, and TGA, MediPharm leads in pharmaceutical cannabinoids. They manufacture authorized medical cannabis products in compliance with strict regulations, including products for the Brazilian market under Resolution 327/19. By acquiring VIVO Cannabis, MediPharm expanded its reach to Canada, Australia, and Germany, offering a full suite of cannabis products to domestic and international medical markets.

News

MediPharm Labs Settles an Outstanding Claim for $9M

Rhea-AI Summary
MediPharm Labs settles an outstanding claim for $9M
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.66%
Tags
none
-
News

MediPharm Labs Launches new GMP Products to the Australian Medical Cannabis Market

Rhea-AI Summary
MediPharm Labs launches GMP products in Australian medical cannabis market
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.79%
Tags
none
-
News

MediPharm Labs Improves Domestic Sales Gross Margin with Termination of Shelter Cannabis Brands Royalty Agreement

Rhea-AI Summary
MediPharm Labs terminates royalty agreement with Shelter Cannabis Brands, resulting in improved gross margin and flexibility for further investment in driving sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.56%
Tags
none
News

MediPharm Labs Completes Sale of Vacant Land for Cash Proceeds of $1.9 million

Rhea-AI Summary
MediPharm Labs completes sale of vacant land for cash proceeds of $1.9 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.72%
Tags
none
-
News

MediPharm Labs Publishes Study Investigating Medical Cannabis Impacts on Anxiety and Depression Outcomes in Fibromyalgia Patients

Rhea-AI Summary
MediPharm Labs subsidiary Harvest Medicine published a study on Fibromyalgia and cannabis in the American Journal of Endocannabinoid Medicine. The study included over 800 patient assessments and showed a significant decrease in illness severity, depression, and anxiety scores. Medical cannabis may be effective in managing fibromyalgia and associated symptoms.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.29%
Tags
none
-
News

MediPharm Labs Reports Second Quarter Results with Doubling of Revenue and Record Margin Growth

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.13%
Tags
earnings
News

MediPharm Labs Sets Date to Report Second Quarter 2023 Financial Results

Rhea-AI Summary
MediPharm Labs Corp. will release its second quarter financial results for the period ended June 30, 2023, on August 14, 2023. The executive management team will host a conference call and audio webcast to discuss the results. MediPharm Labs specializes in the development and manufacture of cannabis concentrates and derivative products. The company has invested in state-of-the-art technology and facilities. In 2021, MediPharm Labs became the only company in North America to hold a domestic Good Manufacturing Licence for the extraction of natural cannabinoids.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags
conferences earnings
-
News

MediPharm Labs Makes First Delivery of Cannabis Clinical Trial Material to US Research Partner and Provides Update on US FDA Status

Rhea-AI Summary
MediPharm Labs Corp. has made its first delivery of pharmaceutical cannabis product to the United States for use in an NIH funded clinical trial. This is the first Phase 2 clinical trial of its kind sourced from a Canadian Licensed Producer. MediPharm also completed a US FDA inspection at its Barrie, Ontario facility, becoming a registered foreign drug manufacturing site with the FDA. The company believes it is the only Canadian Pharmaceutical company or LP with this registration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
20.45%
Tags
clinical trial
-
News

MediPharm Labs Announces Change of Auditor

Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.13%
Tags
none
News

MediPharm Labs Provides Update on Clinical Trial Progress Including FDA Approval of Partner Study

Rhea-AI Summary

MediPharm Labs Corp. (TSX: LABS, OTCQX: MEDIF) announced significant advancements in cannabis research, providing clinical trial materials and support to multiple partners. The company has obtained FDA approval for an Investigational New Drug to treat Alzheimer's Agitation Disorder. MediPharm has also delivered clinical trial materials for studies on post-surgical pain and insomnia in depressive disorders. With its GMP Drug Establishment License and FDA registered facility, the company is positioned to support global trials. MediPharm continues to invest in developing cannabis-derived pharmaceutical drugs and aims to support further clinical trials across North America.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.45%
Tags
clinical trial fda approval

FAQ

What is the current stock price of MEDIPHARM LABS (MEDIF)?

The current stock price of MEDIPHARM LABS (MEDIF) is $0.043572 as of December 24, 2024.

What is the market cap of MEDIPHARM LABS (MEDIF)?

The market cap of MEDIPHARM LABS (MEDIF) is approximately 20.5M.

What certifications does MediPharm Labs Corp hold?

MediPharm Labs Corp holds GMP certification from ANVISA, FDA, EU, and TGA.

What products does MediPharm Labs manufacture?

MediPharm Labs manufactures authorized medical cannabis products under strict regulatory compliance, including products for the Brazilian market.

What was the significance of acquiring VIVO Cannabis?

The acquisition of VIVO Cannabis expanded MediPharm's reach to Canada, Australia, and Germany, offering a full suite of cannabis products to domestic and international medical markets.

When was MediPharm Labs Corp founded?

MediPharm Labs Corp was founded in 2015.

What is the core business of MediPharm Labs Corp?

The core business of MediPharm Labs Corp is to specialize in the development and manufacture of purified, pharmaceutical-quality cannabis concentrates and derivative products.

What is the current financial position of MediPharm Labs Corp?

MediPharm Labs Corp is in a strong financial position, with significant revenue growth and improving Adjusted EBITDA.

In which markets does MediPharm Labs operate?

MediPharm Labs operates in domestic and international medical markets, including Canada, Australia, Germany, and Brazil.

What regulatory certifications did MediPharm Labs receive in 2021?

In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada.

What is the significance of MediPharm Labs' GMP certification?

MediPharm Labs' GMP certification ensures adherence to strict manufacturing processes and facilitates access to global markets.

What is the expected growth of the Brazilian medical cannabis market?

The Brazilian medical cannabis market is expected to reach $380 million CAD in 2025.

Stock MEDIF logo
MEDIPHARM LABS CORP

OTC:MEDIF

MEDIF Rankings

N/A Ranked by Market Cap
N/A Ranked by Dividends

MEDIF Stock Data

20.54M
382.53M
4.45%
0.71%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
United States of America
Barrie